|
May 9
|
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
|
|
May 7
|
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
|
|
Dec 22
|
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
|
|
Dec 20
|
PureTech Year End Update and Outlook for 2024
|
|
Dec 7
|
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
|
|
Nov 29
|
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
|
|
Aug 22
|
PureTech Health: Notice of Half-Yearly Results
|
|
Jun 21
|
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
|
|
May 4
|
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
|
|
Apr 29
|
Full Year 2023 PureTech Health PLC Earnings Call
|